BRAF and glioblastoma: This is notwithstanding the potential radiosensitization-independent benefits of NVP-AUY922 previously shown, such as improvement in lung metastasis in terms of number, size and lung volume occupied in BRAF mutant WM266.4 melanoma xenografts, absence of lymph node metastasis in PTEN-null human prostate carcinoma (PC3LN3) model and decreased microvessel density in U87G PTEN-null glioblastoma xenografts [20].